國鼎生物科技

協助我們的全球數百位科學家，仍以各項專長解開各種癌病治療之鑰，引領國鼎生技將新藥能於未來成功在全球上市為目標，紓解癌症無新藥可用的窘境，使病患能快速康復，改善生活品質，打破「台灣沒有能力研發新藥」的迷思及西方藥廠長期把持的現實，也期望這一天很快到來。還有許多疾病有待全球科學家努力，國鼎生技也會繼癌症治療之後，提出其他疾病治療的新藥。基礎越穩，發展就越順暢；消除病痛才是幸福快樂的泉源最深層意義。

我們要努力的方向還很多，一個新藥代表一個產業，因為有專利保護，未來20年要如何經營一個品牌將是重大里程，而在未來引進或合作或結盟國際上有經驗的藥事專業人才及機構。對於一個品牌價值隨時間而發揮及向全球做系統性佈局，所以國鼎生技的價值鏈將環環相扣，也表示一個醫藥集團逐漸形成。期勉大家已經做的很好，未來也會更好，也是你我所共同創造的成果！

GBC aimed to discover the new drugs especially in anti-cancer and anti-atherosclerosis from the screening platforms during 2002 - 2004. GBC continuously develops its pipeline of new drugs and is currently expanding into new drug development.

Antroquinonol® has applied for compound and use patents worldwide. Antroquinonol® was approved by USFDA in January and TFDA in April of 2010 for IND. Because of the great performance in efficacy and non-systemic toxicity that appeared in cancer treatment that we had in Taiwan, GDAC currently has been exported to China, Singapore, Malaysia and Japan. GoldenBiotech started the phase I clinical trial on NSCLC patients and signed the contract agreement with PharmaNet as our CRO to monitor the clinical trial at medical centers in the US and Taiwan.

Clinical trials for other indications will be started after completing the phase 1 study, including trials of breast cancer, prostate cancer, skin cancer, HCCs and pancreatic cancer. GoldenBiotech has set up subsidiaries in the US, Japan and China for customer service support and built up the cGMP facility for API supply in order to enhance the collaboration of a worldwide market.

GoldenBiotech is the leading company in the Antrodia camphorata industry and Antroquinonol® is the only NCE in oncology filed IND that was successfully approved by the USFDA in the history of Taiwan.